An FDA advisory panel votes narrowly to recommend easing current restrictions that bar compounding pharmacies from producing certain injectable peptides that are not approved for medical use. Multiple outlets report that the panel’s recommendations would allow compounding for peptides including BPC-157 and KPV, which have gained attention through wellness influencers and public figures. The panel is described as issuing recommendations after a series of votes, with the final outcomes characterized as close. Government scientists and other reviewers cited limited evidence on safety and effectiveness for the medical uses claimed for these substances, noting that the peptides have not been shown to be safe or effective in appropriate clinical studies.
The Guardian additionally reports concerns about potential conflicts of interest, pointing to the panel’s membership and noting that some members have links to the peptides industry. Despite those concerns and the warnings from government scientists, the committee’s recommendation would, if adopted by the FDA, broaden what compounding pharmacies are allowed to produce. The reports agree the key action is a change in FDA restrictions affecting injectable peptide compounding rather than approval of the peptides themselves as drugs.
